Products

What will AGI do for Bacitracin/diperodon/neomycin/polymyxin b?

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.

How AGI delivers it

Four ways AGI delivers for Bacitracin/diperodon/neomycin/polymyxin b

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Bacitracin/diperodon/neomycin/polymyxin b, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Bacitracin/diperodon/neomycin/polymyxin b, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Bacitracin/diperodon/neomycin/polymyxin b connects

measured by

  • Assay Potency in Unitsmodel
  • Content Uniformitymodel
  • Microbial Sterilitymodel